Become part of the Cancer Research UK Oxford Centre Community
Latest news

Bowel cancer patients going undiagnosed due to COVID distruption
A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020

“The Oxford Classic” classification system uncovers new information about ovarian cancers
Oxford cancer researchers have developed a new way of subtyping ovarian cancer that enables the accurate prediction of patient outcome and sheds light onto the role the immune system plays in ovarian cancer response to treatment.

Oxford spin out financed $6.8m for research into oncolytic therapies
Oxford spin out company Theolytics has closed a $6.8m deal to support their work into developing novel cancer therapies from viruses

Being a part of cancer drug discoveries
Susan Cakebread, gives her account of being on an experimental drug trial here in Oxford

Investigating the effects of co-morbidities on liver cancer risk
Dr Philippa Matthews and colleagues review the associations between liver cancer risk and co-morbidities and other metabolic factors in individuals with chronic hepatitis B virus infection.

Potential of DNA-based blood tests for detecting pancreatic cancer earlier
Dr Shivan Sivakumar and colleagues evaluate the current progress and future potential in using genetic and epigenetic methods for detecting pancreatic cancer DNA in the blood

Bioengineering the human gut
An interdisciplinary collaboration generates an advanced model of the human gastrointestinal tract with broad applications for disease research and regenerative medicine

Pancreatic Cancer Awareness Month
A round up of Pancreatic Cancer Awareness Month at the University of Oxford

SCALOP team discover new pancreatic cancer biomarker
The SCALOP clinical trial team have uncovered a new therapeutic target for locally advanced pancreatic cancer. Read more about it and the next steps for the SCALOP-2 trial.